Physician

Anthony S Padula, M.D.

According to 2025 Medicare claims, Anthony Padula, M.D. (NPI: 1235103813) practices rheumatology in the Oakland-Fremont-Berkeley, CA market, with the plurality of this provider's patient population coming from Contra Costa, CA. This provider's primary affiliated billing organization is ARTHRITIS AND RHEUMATOLOGY MEDICAL ASSOCIATES, INC (NPI: 1154403483; TIN: 943295212) and primary practice location at 94598-3007.

Padula's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 348 traditional Medicare patients, billed 144,684 HCPCS/CPT codes, and received $1,540,589 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,714 prescription claims across 334 beneficiaries totaling $1,751,323 in drug costs, led by Enbrel Sureclick (Etanercept). Open Payments data shows 246 records totaling $62,220. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $152,054 to $1,540,589. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $705,920 to $1,751,323. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	360	4,546	$152,054
2016	380	3,707	$139,287
2017	400	4,583	$158,048
2018	422	3,904	$160,183
2019	369	2,862	$130,686
2020	338	2,895	$121,140
2021	327	104,001	$1,229,656
2022	315	157,518	$1,580,457
2023	313	161,191	$1,521,137
2024	348	144,684	$1,540,589

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	300	2,460	$705,920
2016	305	2,830	$704,418
2017	318	3,116	$1,014,818
2018	333	3,101	$1,326,453
2019	303	2,624	$1,396,889
2020	294	2,566	$1,458,932
2021	292	2,508	$1,377,009
2022	296	2,310	$1,312,678
2023	306	2,481	$1,516,966
2024	334	2,714	$1,751,323

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	37	37	$182
96413	Administration of chemotherapy into vein, 1 hour or less	72	452	$138
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	333	988	$111
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	292	719	$14
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	46	234	$1

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Sureclick	Etanercept	48	1,456	$371,682
Humira(Cf) Pen	Adalimumab	48	1,344	$322,432
Cimzia (2 Pack)	Certolizumab Pegol	48	1,344	$282,139
Kevzara	Sarilumab	33	980	$144,240
Enbrel	Etanercept	18	504	$129,717

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	246	$62,220	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anthony S. Padula, M.D.?

Tedicare shows public-source Medicare data for Anthony S. Padula, M.D. (NPI 1235103813), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anthony S. Padula, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Anthony S. Padula, M.D.?

Anthony S. Padula, M.D. is linked to ARTHRITIS AND RHEUMATOLOGY MEDICAL ASSOCIATES, INC (billing NPI 1154403483) in the available physician profile data.

Does Anthony S. Padula, M.D. have Open Payments data?

Anthony S. Padula, M.D. has 246 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.